imipramine has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 1 |
| Garg, R | 1 |
| Staines, DR | 1 |
2 other studies available for imipramine and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2009 |
Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
Topics: Autoimmune Diseases; Cyclic AMP; Fatigue Syndrome, Chronic; Humans; Imipramine; Neuropeptides; Phosp | 2006 |